Literature DB >> 27575357

Clinical Relevance of Fluid Challenge in Patients Evaluated for Pulmonary Hypertension.

Michele D'Alto1, Emanuele Romeo2, Paola Argiento2, Yoshiki Motoji3, Anna Correra2, Giovanni Maria Di Marco2, Agostino Mattera Iacono2, Rosaria Barracano2, Antonello D'Andrea2, Gaetano Rea4, Berardo Sarubbi2, Maria Giovanna Russo2, Robert Naeije3.   

Abstract

BACKGROUND: Fluid challenge may help in the differential diagnosis between pre- and postcapillary pulmonary hypertension (PH). However, the test is still in need of standardization and better defined clinical relevance.
METHODS: Two hundred twelve patients referred for PH underwent a right-sided heart catheterization with measurements before and after rapid infusion of 7 mL/kg of saline. PH was defined as mean pulmonary artery pressure ≥ 25 mm Hg, and postcapillary PH was defined as pulmonary artery wedge pressure (PAWP) > 15 mm Hg. An increase in PAWP ≥ 18 mm Hg was considered diagnostic for postcapillary PH. At baseline, 66 patients received a diagnosis of no PH; 22, of postcapillary PH; and 124, of precapillary PH (mostly pulmonary arterial hypertension).
RESULTS: After fluid challenge, five of 66 patients with no PH (8%) and eight of 124 with precapillary PH (6%) had the diagnosis reclassified as postcapillary PH. Fluid challenge was associated with an increase in PAWP by 7 ± 2 mm Hg in postcapillary PH and 3 ± 1 mm Hg in both precapillary PH and no-PH groups. Between-group differences were significant, but there was overlap. There were no adverse events related to fluid challenge. Prediction bands calculated from quadratic fits of the PAWP responses in pooled control subjects with no PH and patients with precapillary PH helped confirm 18 mm Hg as the cutoff for diagnosing postcapillary PH.
CONCLUSIONS: Fluid challenge with 7 mL/kg saline increases PAWP, more in postcapillary than in precapillary PH or in control subjects with no PH. A cutoff value of 18 mm Hg allows reclassification of 6% to 8% of patients with precapillary PH or normal hemodynamic characteristics at baseline.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  fluid challenge; heart catheterization; heart failure; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27575357     DOI: 10.1016/j.chest.2016.08.1439

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

2.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 3.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 4.  A review of exercise pulmonary hypertension in systemic sclerosis.

Authors:  Faisal Shaikh; Zafia Anklesaria; Tasneam Shagroni; Rajeev Saggar; Luna Gargani; Eduardo Bossone; Michael Ryan; Richard Channick; Rajan Saggar
Journal:  J Scleroderma Relat Disord       Date:  2019-06-14

5.  The Role of Pulmonary Artery Wedge Pressure on the Incidence of Atrial Fibrillation and Atrial Tachycardias in Patients With Isolated Pre-capillary Pulmonary Hypertension.

Authors:  M Dusik; Z Fingrova; D Ambroz; P Jansa; A Linhart; S Havranek
Journal:  Physiol Res       Date:  2021-10-30       Impact factor: 1.881

Review 6.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 7.  Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week.

Authors:  Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford
Journal:  J Am Coll Cardiol       Date:  2020-12-01       Impact factor: 24.094

Review 8.  Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.

Authors:  Andrea R Levine; Marc A Simon; Mark T Gladwin
Journal:  Trends Cardiovasc Med       Date:  2018-08-17       Impact factor: 6.677

9.  Invasive Hemodynamic and Metabolic Evaluation of HFpEF.

Authors:  J Emanuel Finet; Erik H Van Iterson; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-03-26

10.  Under Pressure: Right Heart Catheterization and Provocative Testing for Diagnosing Pulmonary Hypertension.

Authors:  Isaac Tea; Imad Hussain
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.